Mizuho Securities analyst Salim Syed maintained a Buy rating on Unity Biotechnology (UBX) today and set a price target of $33.00. The company’s shares closed last Monday at $6.52.
According to TipRanks.com, Syed has 0 stars on 0-5 star ranking scale with an average return of -7.7% and a 45.9% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Coherus Biosciences, and Wave Life Sciences.
Unity Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $26.50.
See today’s analyst top recommended stocks >>
Based on Unity Biotechnology’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $21.71 million. In comparison, last year the company had a GAAP net loss of $21.92 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Unity Biotechnology, Inc. operates as a biotechnology company engaged in the research and development of therapeutics to extend the human health span. The company was founded by Nathaniel David, Jan van Deursen, Judith Campisi and Daohong Zhou in March 2009 and is headquartered in Brisbane, CA.
